PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies

Prostatic neuroendocrine malignancies represent a spectrum of diseases. Treatment-induced neuroendocrine differentiation (tiNED) in hormonally treated adenocarcinoma has been the subject of a large amount of recent research. However, the identification of neuroendocrine features in treatment-naïve p...

Full description

Saved in:
Bibliographic Details
Published inEuropean radiology Vol. 33; no. 9; pp. 6502 - 6512
Main Authors Cohen, Dan, Hazut Krauthammer, Shir, Fahoum, Ibrahim, Kesler, Mikhail, Even-Sapir, Einat
Format Journal Article
LanguageEnglish
Published Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2023
Springer Nature B.V
Subjects
Adenocarcinoma
Adenocarcinoma - diagnostic imaging
Antigens
Diagnostic Radiology
Differential diagnosis
Differentiation
Fluorine isotopes
Fluorodeoxyglucose F18
Gallium isotopes
Gallium Radioisotopes
Glucose metabolism
Health services
Humans
Imaging
Internal Medicine
Interventional Radiology
Isotopes
Ligands
Male
Malignancy
Medical imaging
Medicine
Medicine & Public Health
Molecular Imaging
Neuroendocrine tumors
Neuroradiology
Nuclear medicine
Positron emission
Positron emission tomography
Positron Emission Tomography Computed Tomography - methods
Prostate - pathology
Prostate cancer
Prostatic Neoplasms - pathology
Radioactive tracers
Radiology
Review
Somatostatin
Tumors
Ultrasound
PET-CT
18F-FDG
Somatostatin
Prostate cancer
PSMA antigen
Online AccessGet full text
ISSN1432-1084
0938-7994
1432-1084
DOI10.1007/s00330-023-09619-8

Cover

Abstract Prostatic neuroendocrine malignancies represent a spectrum of diseases. Treatment-induced neuroendocrine differentiation (tiNED) in hormonally treated adenocarcinoma has been the subject of a large amount of recent research. However, the identification of neuroendocrine features in treatment-naïve prostatic tumor raises a differential diagnosis between prostatic adenocarcinoma with de novo neuroendocrine differentiation (dNED) versus one of the primary prostatic neuroendocrine tumors (P-NETs) and carcinomas (P-NECs). While [ 18 F]FDG is being used as the main PET radiotracer in oncologic imaging and reflects cellular glucose metabolism, other molecules labeled with positron-emitting isotopes, mainly somatostatin-analogues labeled with 68 Ga and prostate-specific membrane antigen (PSMA)-ligands labeled with either 18 F or 68 Ga, are now routinely used in departments of nuclear medicine and molecular imaging, and may be advantageous in imaging prostatic neuroendocrine malignancies. Still, the selection of the preferred PET radiotracer in such cases might be challenging. In the current review, we summarize and discuss published data on these different entities from clinical, biological, and molecular imaging standpoints. Specifically, we review the roles that [ 18 F]FDG, radiolabeled somatostatin-analogues, and radiolabeled PSMA-ligands play in these entities in order to provide the reader with practical recommendations regarding the preferred PET radiotracers for imaging each entity. In cases of tiNED, we conclude that PSMA expression may be low and that [ 18 F]FDG or radiolabeled somatostatin-analogues should be preferred for imaging. In cases of prostatic adenocarcinoma with dNED, we present data that support the superiority of radiolabeled PSMA-ligands. In cases of primary neuroendocrine malignancies, the use of [ 18 F]FDG for imaging high-grade P-NECs and radiolabeled somatostatin-analogues for imaging well-differentiated P-NETs is recommended. Key Points • The preferred PET radiotracer for imaging prostatic neuroendocrine malignancies depends on the specific clinical scenario and pathologic data. • When neuroendocrine features result from hormonal therapy for prostate cancer, PET-CT should be performed with [ 18 F]FDG or radiolabeled somatostatin-analogue rather than with radiolabeled PSMA-ligand. • When neuroendocrine features are evident in newly diagnosed prostate cancer, differentiating adenocarcinoma from primary neuroendocrine malignancy is challenging but crucial for selection of PET radiotracer and for clinical management.
AbstractList Prostatic neuroendocrine malignancies represent a spectrum of diseases. Treatment-induced neuroendocrine differentiation (tiNED) in hormonally treated adenocarcinoma has been the subject of a large amount of recent research. However, the identification of neuroendocrine features in treatment-naïve prostatic tumor raises a differential diagnosis between prostatic adenocarcinoma with de novo neuroendocrine differentiation (dNED) versus one of the primary prostatic neuroendocrine tumors (P-NETs) and carcinomas (P-NECs). While [18F]FDG is being used as the main PET radiotracer in oncologic imaging and reflects cellular glucose metabolism, other molecules labeled with positron-emitting isotopes, mainly somatostatin-analogues labeled with 68Ga and prostate-specific membrane antigen (PSMA)-ligands labeled with either 18F or 68Ga, are now routinely used in departments of nuclear medicine and molecular imaging, and may be advantageous in imaging prostatic neuroendocrine malignancies. Still, the selection of the preferred PET radiotracer in such cases might be challenging. In the current review, we summarize and discuss published data on these different entities from clinical, biological, and molecular imaging standpoints. Specifically, we review the roles that [18F]FDG, radiolabeled somatostatin-analogues, and radiolabeled PSMA-ligands play in these entities in order to provide the reader with practical recommendations regarding the preferred PET radiotracers for imaging each entity. In cases of tiNED, we conclude that PSMA expression may be low and that [18F]FDG or radiolabeled somatostatin-analogues should be preferred for imaging. In cases of prostatic adenocarcinoma with dNED, we present data that support the superiority of radiolabeled PSMA-ligands. In cases of primary neuroendocrine malignancies, the use of [18F]FDG for imaging high-grade P-NECs and radiolabeled somatostatin-analogues for imaging well-differentiated P-NETs is recommended. KEY POINTS: • The preferred PET radiotracer for imaging prostatic neuroendocrine malignancies depends on the specific clinical scenario and pathologic data. • When neuroendocrine features result from hormonal therapy for prostate cancer, PET-CT should be performed with [18F]FDG or radiolabeled somatostatin-analogue rather than with radiolabeled PSMA-ligand. • When neuroendocrine features are evident in newly diagnosed prostate cancer, differentiating adenocarcinoma from primary neuroendocrine malignancy is challenging but crucial for selection of PET radiotracer and for clinical management.Prostatic neuroendocrine malignancies represent a spectrum of diseases. Treatment-induced neuroendocrine differentiation (tiNED) in hormonally treated adenocarcinoma has been the subject of a large amount of recent research. However, the identification of neuroendocrine features in treatment-naïve prostatic tumor raises a differential diagnosis between prostatic adenocarcinoma with de novo neuroendocrine differentiation (dNED) versus one of the primary prostatic neuroendocrine tumors (P-NETs) and carcinomas (P-NECs). While [18F]FDG is being used as the main PET radiotracer in oncologic imaging and reflects cellular glucose metabolism, other molecules labeled with positron-emitting isotopes, mainly somatostatin-analogues labeled with 68Ga and prostate-specific membrane antigen (PSMA)-ligands labeled with either 18F or 68Ga, are now routinely used in departments of nuclear medicine and molecular imaging, and may be advantageous in imaging prostatic neuroendocrine malignancies. Still, the selection of the preferred PET radiotracer in such cases might be challenging. In the current review, we summarize and discuss published data on these different entities from clinical, biological, and molecular imaging standpoints. Specifically, we review the roles that [18F]FDG, radiolabeled somatostatin-analogues, and radiolabeled PSMA-ligands play in these entities in order to provide the reader with practical recommendations regarding the preferred PET radiotracers for imaging each entity. In cases of tiNED, we conclude that PSMA expression may be low and that [18F]FDG or radiolabeled somatostatin-analogues should be preferred for imaging. In cases of prostatic adenocarcinoma with dNED, we present data that support the superiority of radiolabeled PSMA-ligands. In cases of primary neuroendocrine malignancies, the use of [18F]FDG for imaging high-grade P-NECs and radiolabeled somatostatin-analogues for imaging well-differentiated P-NETs is recommended. KEY POINTS: • The preferred PET radiotracer for imaging prostatic neuroendocrine malignancies depends on the specific clinical scenario and pathologic data. • When neuroendocrine features result from hormonal therapy for prostate cancer, PET-CT should be performed with [18F]FDG or radiolabeled somatostatin-analogue rather than with radiolabeled PSMA-ligand. • When neuroendocrine features are evident in newly diagnosed prostate cancer, differentiating adenocarcinoma from primary neuroendocrine malignancy is challenging but crucial for selection of PET radiotracer and for clinical management.
Prostatic neuroendocrine malignancies represent a spectrum of diseases. Treatment-induced neuroendocrine differentiation (tiNED) in hormonally treated adenocarcinoma has been the subject of a large amount of recent research. However, the identification of neuroendocrine features in treatment-naïve prostatic tumor raises a differential diagnosis between prostatic adenocarcinoma with de novo neuroendocrine differentiation (dNED) versus one of the primary prostatic neuroendocrine tumors (P-NETs) and carcinomas (P-NECs). While [18F]FDG is being used as the main PET radiotracer in oncologic imaging and reflects cellular glucose metabolism, other molecules labeled with positron-emitting isotopes, mainly somatostatin-analogues labeled with 68Ga and prostate-specific membrane antigen (PSMA)-ligands labeled with either 18F or 68Ga, are now routinely used in departments of nuclear medicine and molecular imaging, and may be advantageous in imaging prostatic neuroendocrine malignancies. Still, the selection of the preferred PET radiotracer in such cases might be challenging. In the current review, we summarize and discuss published data on these different entities from clinical, biological, and molecular imaging standpoints. Specifically, we review the roles that [18F]FDG, radiolabeled somatostatin-analogues, and radiolabeled PSMA-ligands play in these entities in order to provide the reader with practical recommendations regarding the preferred PET radiotracers for imaging each entity. In cases of tiNED, we conclude that PSMA expression may be low and that [18F]FDG or radiolabeled somatostatin-analogues should be preferred for imaging. In cases of prostatic adenocarcinoma with dNED, we present data that support the superiority of radiolabeled PSMA-ligands. In cases of primary neuroendocrine malignancies, the use of [18F]FDG for imaging high-grade P-NECs and radiolabeled somatostatin-analogues for imaging well-differentiated P-NETs is recommended.Key Points• The preferred PET radiotracer for imaging prostatic neuroendocrine malignancies depends on the specific clinical scenario and pathologic data.• When neuroendocrine features result from hormonal therapy for prostate cancer, PET-CT should be performed with [18F]FDG or radiolabeled somatostatin-analogue rather than with radiolabeled PSMA-ligand.• When neuroendocrine features are evident in newly diagnosed prostate cancer, differentiating adenocarcinoma from primary neuroendocrine malignancy is challenging but crucial for selection of PET radiotracer and for clinical management.
Prostatic neuroendocrine malignancies represent a spectrum of diseases. Treatment-induced neuroendocrine differentiation (tiNED) in hormonally treated adenocarcinoma has been the subject of a large amount of recent research. However, the identification of neuroendocrine features in treatment-naïve prostatic tumor raises a differential diagnosis between prostatic adenocarcinoma with de novo neuroendocrine differentiation (dNED) versus one of the primary prostatic neuroendocrine tumors (P-NETs) and carcinomas (P-NECs). While [ F]FDG is being used as the main PET radiotracer in oncologic imaging and reflects cellular glucose metabolism, other molecules labeled with positron-emitting isotopes, mainly somatostatin-analogues labeled with Ga and prostate-specific membrane antigen (PSMA)-ligands labeled with either F or Ga, are now routinely used in departments of nuclear medicine and molecular imaging, and may be advantageous in imaging prostatic neuroendocrine malignancies. Still, the selection of the preferred PET radiotracer in such cases might be challenging. In the current review, we summarize and discuss published data on these different entities from clinical, biological, and molecular imaging standpoints. Specifically, we review the roles that [ F]FDG, radiolabeled somatostatin-analogues, and radiolabeled PSMA-ligands play in these entities in order to provide the reader with practical recommendations regarding the preferred PET radiotracers for imaging each entity. In cases of tiNED, we conclude that PSMA expression may be low and that [ F]FDG or radiolabeled somatostatin-analogues should be preferred for imaging. In cases of prostatic adenocarcinoma with dNED, we present data that support the superiority of radiolabeled PSMA-ligands. In cases of primary neuroendocrine malignancies, the use of [ F]FDG for imaging high-grade P-NECs and radiolabeled somatostatin-analogues for imaging well-differentiated P-NETs is recommended. KEY POINTS: • The preferred PET radiotracer for imaging prostatic neuroendocrine malignancies depends on the specific clinical scenario and pathologic data. • When neuroendocrine features result from hormonal therapy for prostate cancer, PET-CT should be performed with [ F]FDG or radiolabeled somatostatin-analogue rather than with radiolabeled PSMA-ligand. • When neuroendocrine features are evident in newly diagnosed prostate cancer, differentiating adenocarcinoma from primary neuroendocrine malignancy is challenging but crucial for selection of PET radiotracer and for clinical management.
Prostatic neuroendocrine malignancies represent a spectrum of diseases. Treatment-induced neuroendocrine differentiation (tiNED) in hormonally treated adenocarcinoma has been the subject of a large amount of recent research. However, the identification of neuroendocrine features in treatment-naïve prostatic tumor raises a differential diagnosis between prostatic adenocarcinoma with de novo neuroendocrine differentiation (dNED) versus one of the primary prostatic neuroendocrine tumors (P-NETs) and carcinomas (P-NECs). While [ 18 F]FDG is being used as the main PET radiotracer in oncologic imaging and reflects cellular glucose metabolism, other molecules labeled with positron-emitting isotopes, mainly somatostatin-analogues labeled with 68 Ga and prostate-specific membrane antigen (PSMA)-ligands labeled with either 18 F or 68 Ga, are now routinely used in departments of nuclear medicine and molecular imaging, and may be advantageous in imaging prostatic neuroendocrine malignancies. Still, the selection of the preferred PET radiotracer in such cases might be challenging. In the current review, we summarize and discuss published data on these different entities from clinical, biological, and molecular imaging standpoints. Specifically, we review the roles that [ 18 F]FDG, radiolabeled somatostatin-analogues, and radiolabeled PSMA-ligands play in these entities in order to provide the reader with practical recommendations regarding the preferred PET radiotracers for imaging each entity. In cases of tiNED, we conclude that PSMA expression may be low and that [ 18 F]FDG or radiolabeled somatostatin-analogues should be preferred for imaging. In cases of prostatic adenocarcinoma with dNED, we present data that support the superiority of radiolabeled PSMA-ligands. In cases of primary neuroendocrine malignancies, the use of [ 18 F]FDG for imaging high-grade P-NECs and radiolabeled somatostatin-analogues for imaging well-differentiated P-NETs is recommended. Key Points • The preferred PET radiotracer for imaging prostatic neuroendocrine malignancies depends on the specific clinical scenario and pathologic data. • When neuroendocrine features result from hormonal therapy for prostate cancer, PET-CT should be performed with [ 18 F]FDG or radiolabeled somatostatin-analogue rather than with radiolabeled PSMA-ligand. • When neuroendocrine features are evident in newly diagnosed prostate cancer, differentiating adenocarcinoma from primary neuroendocrine malignancy is challenging but crucial for selection of PET radiotracer and for clinical management.
Author Kesler, Mikhail
Hazut Krauthammer, Shir
Fahoum, Ibrahim
Cohen, Dan
Even-Sapir, Einat
Author_xml – sequence: 1
  givenname: Dan
  orcidid: 0000-0001-8804-4806
  surname: Cohen
  fullname: Cohen, Dan
  email: cohendandan@gmail.com
  organization: Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center
– sequence: 2
  givenname: Shir
  orcidid: 0000-0001-8165-3019
  surname: Hazut Krauthammer
  fullname: Hazut Krauthammer, Shir
  organization: Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center
– sequence: 3
  givenname: Ibrahim
  surname: Fahoum
  fullname: Fahoum, Ibrahim
  organization: Institute of Pathology, Tel-Aviv Sourasky Medical Center
– sequence: 4
  givenname: Mikhail
  orcidid: 0000-0003-0786-084X
  surname: Kesler
  fullname: Kesler, Mikhail
  organization: Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center
– sequence: 5
  givenname: Einat
  orcidid: 0000-0003-2487-0310
  surname: Even-Sapir
  fullname: Even-Sapir, Einat
  organization: Department of Nuclear Medicine, Tel-Aviv Sourasky Medical Center, Sackler Faculty of Medicine, Tel Aviv University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37052659$$D View this record in MEDLINE/PubMed
BookMark eNp9kctO3jAQha2KqlzaF2CBLLHpJu34ksReIkQBCald0LXl2JMfo8QGO6Hi7Wv46UUsWHlkfcc-c84-2YkpIiGHDL4wgP5rARACGuCiAd0x3ah3ZI9JwRsGSu78N--S_VJuAUAz2X8gu6KHlnet3iPDj7Nrmq0PacnWYS50TJn-ukkTNkPyjzRE-hAeEp3rjVsnm2mY7SbEDU0jvcupLHYJjkZcc8Lok8shIp3tFDbRRhewfCTvRzsV_PRyHpCf386uTy-aq-_nl6cnV40Tfbs0bQde8H5UCHUXN6AdYWADl50aNFMgvev6UWoA75TnqKUWqGTbsVFwJ704IJ-371ZX9yuWxcyhOJwmGzGtxXAF0HHVal3R41fobVpzrO4qJVWrtOxEpY5eqHWY0Zu7XFfPj-ZPehXgW8DVHErG8S_CwDxVZLYVmVqRea7IqCpSr0QuPGWYYm0gTG9LxVZa6j9xg_mf7TdUvwH8GqTh
CitedBy_id crossref_primary_10_3390_tomography11030029
crossref_primary_10_2967_jnumed_124_268020
crossref_primary_10_3390_cancers15174404
Cites_doi 10.1053/hp.2000.7295
10.1097/RLU.0000000000002013
10.1111/iju.13526
10.3390/biomedicines10030689
10.5489/cuaj.7268
10.1186/s13550-020-00640-2
10.14740/wjon739w
10.1111/j.1464-410x.1995.tb07385.x
10.1007/s00259-013-2361-7
10.5858/arpa.2019-0434-RA
10.1080/028418602320405005
10.3389/fonc.2021.683793
10.1016/j.eururo.2004.09.007
10.2967/jnumed.116.178095
10.1097/RLU.0000000000001618
10.1056/NEJMoa2107322
10.1038/pcan.2012.4
10.1111/bju.15086
10.1007/978-3-030-13601-7_6
10.1023/a:1007175924082
10.7759/cureus.8356
10.1186/s13256-021-02830-5
10.1007/s11912-020-01003-9
10.3389/fonc.2020.580617
10.3978/j.issn.2305-5839.2015.06.10
10.1038/s41598-018-33774-4
10.1186/1477-7819-6-64
10.1097/PAS.0000000000000208
10.1530/ERC-18-0226
10.1016/S0022-5347(02)80307-X
10.1016/S0140-6736(20)30314-7
10.1148/rg.352140164
10.1148/rg.2017170035
10.1200/JCO.2007.12.4487
10.1097/RLU.0000000000001424
10.1016/S1470-2045(21)00572-6
10.1001/jamaoncol.2019.0096
10.1002/(SICI)1097-0045(1998)8+<37::AID-PROS7>3.0.CO;2-D
10.1186/s13046-022-02255-y
10.1007/s12022-016-9421-z
10.1148/rg.2018170108
10.1038/s41698-022-00272-w
10.1002/(sici)1097-0045(19990501)39:2<135::aid-pros9>3.0.co;2-s
10.1038/modpathol.2017.164
10.1111/j.1365-2559.2011.04039.x
10.1016/j.clgc.2018.07.009
10.1200/JCO.2004.11.089
10.1158/1078-0432.CCR-09-1759
10.3389/fonc.2014.00060
10.1158/2159-8290.CD-11-0130
10.2967/jnumed.118.219501
10.1007/s00259-009-1349-9
10.1155/2011/543272
10.20517/cdr.2020.42
10.1016/j.biopha.2008.01.010
10.2967/jnumed.106.035667
10.1002/cncr.23469
10.1002/1097-0142(19941001)74:7<1899::aid-cncr2820740712>3.0.co;2-u
10.1002/pros.22831
10.3390/diagnostics12061387
10.1016/j.annonc.2020.06.011
10.1111/j.1464-410X.2011.10523.x
10.1016/j.humpath.2008.07.014
10.1056/NEJM198908173210702
10.1016/j.eururo.2016.02.028
10.1159/000499883
10.3389/fonc.2020.585213
10.1007/BF03347481
10.1007/s00428-012-1259-2
10.2967/jnumed.108.060236
10.1016/S0022-5347(01)62909-4
10.1038/s41391-021-00332-5
10.1097/00000478-200606000-00003
10.1016/j.eururo.2019.01.049
10.1007/s11307-009-0230-3
10.1097/PAS.0b013e318058a96b
ContentType Journal Article
Copyright The Author(s), under exclusive licence to European Society of Radiology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
2023. The Author(s), under exclusive licence to European Society of Radiology.
Copyright_xml – notice: The Author(s), under exclusive licence to European Society of Radiology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
– notice: 2023. The Author(s), under exclusive licence to European Society of Radiology.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QO
7RV
7X7
7XB
88E
8AO
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
KB0
LK8
M0S
M1P
M7P
NAPCQ
P5Z
P62
P64
PHGZM
PHGZT
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
7X8
DOI 10.1007/s00330-023-09619-8
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Biotechnology Research Abstracts
Nursing & Allied Health Database
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
Natural Science Collection
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
ProQuest Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Biological Sciences
Health & Medical Collection (Alumni)
Medical Database
Biological Science Database
Nursing & Allied Health Premium
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Central Student
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
ProQuest Health & Medical Research Collection
Health Research Premium Collection
Biotechnology Research Abstracts
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Health & Medical Research Collection
Biological Science Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Advanced Technologies & Aerospace Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Advanced Technologies & Aerospace Database
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
ProQuest Central Student
MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 3
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1432-1084
EndPage 6512
ExternalDocumentID 37052659
10_1007_s00330_023_09619_8
Genre Journal Article
Review
GroupedDBID ---
-53
-5E
-5G
-BR
-EM
-Y2
-~C
.86
.VR
04C
06C
06D
0R~
0VY
1N0
1SB
2.D
203
28-
29G
29~
2J2
2JN
2JY
2KG
2KM
2LR
2P1
2VQ
2~H
30V
36B
3V.
4.4
406
408
409
40D
40E
53G
5GY
5QI
5VS
67Z
6NX
6PF
7RV
7X7
88E
8AO
8FE
8FG
8FH
8FI
8FJ
8TC
8UJ
95-
95.
95~
96X
AAAVM
AABHQ
AACDK
AAHNG
AAIAL
AAJBT
AAJKR
AANXM
AANZL
AARHV
AARTL
AASML
AATNV
AATVU
AAUYE
AAWCG
AAWTL
AAYIU
AAYQN
AAYTO
AAYZH
ABAKF
ABBBX
ABBXA
ABDZT
ABECU
ABFTV
ABHLI
ABHQN
ABIPD
ABJNI
ABJOX
ABKCH
ABKTR
ABMNI
ABMQK
ABNWP
ABPLI
ABQBU
ABQSL
ABSXP
ABTEG
ABTKH
ABTMW
ABULA
ABUWG
ABUWZ
ABWNU
ABXPI
ACAOD
ACBXY
ACDTI
ACGFO
ACGFS
ACHSB
ACHVE
ACHXU
ACIHN
ACIWK
ACKNC
ACMDZ
ACMLO
ACOKC
ACOMO
ACPIV
ACPRK
ACREN
ACUDM
ACZOJ
ADBBV
ADHHG
ADHIR
ADIMF
ADINQ
ADJJI
ADKNI
ADKPE
ADOJX
ADRFC
ADTPH
ADURQ
ADYFF
ADYOE
ADZKW
AEAQA
AEBTG
AEFIE
AEFQL
AEGAL
AEGNC
AEJHL
AEJRE
AEKMD
AEMSY
AENEX
AEOHA
AEPYU
AESKC
AETLH
AEVLU
AEXYK
AFBBN
AFEXP
AFJLC
AFKRA
AFLOW
AFQWF
AFRAH
AFWTZ
AFYQB
AFZKB
AGAYW
AGDGC
AGGDS
AGJBK
AGMZJ
AGQEE
AGQMX
AGRTI
AGVAE
AGWIL
AGWZB
AGYKE
AHAVH
AHBYD
AHIZS
AHKAY
AHMBA
AHSBF
AHYZX
AIAKS
AIGIU
AIIXL
AILAN
AITGF
AJBLW
AJRNO
AJZVZ
AKMHD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALWAN
AMKLP
AMTXH
AMXSW
AMYLF
AMYQR
AOCGG
ARAPS
ARMRJ
ASPBG
AVWKF
AXYYD
AZFZN
B-.
BA0
BBNVY
BBWZM
BDATZ
BENPR
BGLVJ
BGNMA
BHPHI
BKEYQ
BMSDO
BPHCQ
BSONS
BVXVI
CAG
CCPQU
COF
CS3
CSCUP
DDRTE
DL5
DNIVK
DPUIP
DU5
EBD
EBLON
EBS
ECF
ECT
EIHBH
EIOEI
EJD
EMB
EMOBN
EN4
ESBYG
EX3
F5P
FEDTE
FERAY
FFXSO
FIGPU
FINBP
FNLPD
FRRFC
FSGXE
FWDCC
FYUFA
G-Y
G-Z
GGCAI
GGRSB
GJIRD
GNWQR
GQ6
GQ7
GQ8
GRRUI
GXS
H13
HCIFZ
HF~
HG5
HG6
HMCUK
HMJXF
HQYDN
HRMNR
HVGLF
HZ~
I-F
I09
IHE
IJ-
IKXTQ
IMOTQ
IWAJR
IXC
IXD
IXE
IZIGR
IZQ
I~X
I~Z
J-C
J0Z
JBSCW
JCJTX
JZLTJ
KDC
KOV
KOW
KPH
LAS
LK8
LLZTM
M1P
M4Y
M7P
MA-
N2Q
N9A
NAPCQ
NB0
NDZJH
NPVJJ
NQJWS
NU0
O9-
O93
O9G
O9I
O9J
OAM
OVD
P19
P2P
P62
P9S
PF0
PQQKQ
PROAC
PSQYO
PT4
PT5
Q2X
QOK
QOR
QOS
R4E
R89
R9I
RHV
RIG
RNI
RNS
ROL
RPX
RRX
RSV
RZK
S16
S1Z
S26
S27
S28
S37
S3B
SAP
SCLPG
SDE
SDH
SDM
SHX
SISQX
SJYHP
SMD
SNE
SNPRN
SNX
SOHCF
SOJ
SPISZ
SRMVM
SSLCW
SSXJD
STPWE
SV3
SZ9
SZN
T13
T16
TEORI
TSG
TSK
TSV
TT1
TUC
U2A
U9L
UDS
UG4
UKHRP
UOJIU
UTJUX
UZXMN
VC2
VFIZW
W23
W48
WJK
WK8
WOW
YLTOR
Z45
Z7R
Z7U
Z7X
Z7Y
Z7Z
Z82
Z83
Z85
Z87
Z88
Z8M
Z8O
Z8R
Z8S
Z8T
Z8V
Z8W
Z8Z
Z91
Z92
ZMTXR
ZOVNA
~EX
AAPKM
AAYXX
ABBRH
ABDBE
ABFSG
ACMFV
ACSTC
ADKFA
AEZWR
AFDZB
AFHIU
AFOHR
AHPBZ
AHWEU
AIXLP
ATHPR
AYFIA
CITATION
PHGZM
PHGZT
ADHKG
CGR
CUY
CVF
ECM
EIF
NPM
7QO
7XB
8FD
8FK
ABRTQ
AZQEC
DWQXO
FR3
GNUQQ
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
PRINS
7X8
ID FETCH-LOGICAL-c375t-560d327f8e0619cbeaf0b1b2468b91804dc67f4900dc8d2e9493e84561f32c4d3
IEDL.DBID 8FG
ISSN 1432-1084
0938-7994
IngestDate Fri Sep 05 08:41:36 EDT 2025
Sat Aug 23 12:22:38 EDT 2025
Thu Apr 03 06:57:05 EDT 2025
Tue Jul 01 00:42:20 EDT 2025
Thu Apr 24 22:52:45 EDT 2025
Fri Feb 21 02:44:14 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 9
Keywords PET-CT
18F-FDG
Somatostatin
Prostate cancer
PSMA antigen
Language English
License 2023. The Author(s), under exclusive licence to European Society of Radiology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c375t-560d327f8e0619cbeaf0b1b2468b91804dc67f4900dc8d2e9493e84561f32c4d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ORCID 0000-0003-2487-0310
0000-0001-8165-3019
0000-0003-0786-084X
0000-0001-8804-4806
PMID 37052659
PQID 2848589463
PQPubID 54162
PageCount 11
ParticipantIDs proquest_miscellaneous_2800628599
proquest_journals_2848589463
pubmed_primary_37052659
crossref_primary_10_1007_s00330_023_09619_8
crossref_citationtrail_10_1007_s00330_023_09619_8
springer_journals_10_1007_s00330_023_09619_8
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-09-01
PublicationDateYYYYMMDD 2023-09-01
PublicationDate_xml – month: 09
  year: 2023
  text: 2023-09-01
  day: 01
PublicationDecade 2020
PublicationPlace Berlin/Heidelberg
PublicationPlace_xml – name: Berlin/Heidelberg
– name: Germany
– name: Heidelberg
PublicationTitle European radiology
PublicationTitleAbbrev Eur Radiol
PublicationTitleAlternate Eur Radiol
PublicationYear 2023
Publisher Springer Berlin Heidelberg
Springer Nature B.V
Publisher_xml – name: Springer Berlin Heidelberg
– name: Springer Nature B.V
References HumphreyPAHistological variants of prostatic carcinoma and their significanceHistopathology2012601597410.1111/j.1365-2559.2011.04039.x22212078
ShayganBZukotynskiKBénardFCanadian Urological Association best practice report: prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate [published correction appears in Can Urol Assoc J. 2021 Aug;15(8):E423]Can Urol Assoc J.202115616217210.5489/cuaj.7268336610938195587
HugginsCHodgesCVStudies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941J Urol.20021672 Pt 2948521:CAS:528:DC%2BD38XhtVylsbw%3D10.1016/S0022-5347(02)80307-X11905923
WallittKLKhanSRDubashSTamHHKhanSBarwickTDClinical PET imaging in prostate cancerRadiographics20173751512153610.1148/rg.201717003528800286
SavelliGMuniABarbieriRNeuroendocrine differentiation of prostate cancer metastases evidenced "in Vivo" by 68Ga-DOTANOC PET/CT: two casesWorld J Oncol201452727610.14740/wjon739w291473815649877
MoroteJAguilarAPlanasJTrillaEDefinition of castrate resistant prostate cancer: new insightsBiomedicines.20221036891:CAS:528:DC%2BB38XosVOltb4%3D10.3390/biomedicines10030689353274918945091
GofritONFrankSMeirovitzANechushtanHOreviMPET/CT With 68Ga-DOTA-TATE for diagnosis of neuroendocrine: differentiation in patients with castrate-resistant prostate cancerClin Nucl Med20174211610.1097/RLU.000000000000142427775942
SleimanWKarrayOAbi AbdallahMLarge-cell neuroendocrine tumor of the prostate: a case report and review of the literatureJ Med Case Rep.202115125410.1186/s13256-021-02830-5339579798103761
ShenKLiuBZhouXThe evolving role of 18F-FDG PET/CT in diagnosis and prognosis prediction in progressive prostate cancerFront Oncol.2021116837931:CAS:528:DC%2BB3sXht1Ghs7fM10.3389/fonc.2021.683793343952518358601
AbrahamssonPANeuroendocrine differentiation in prostatic carcinomaProstate19993921351481:CAS:528:DyaK1MXivF2gtL8%3D10.1002/(sici)1097-0045(19990501)39:2<135::aid-pros9>3.0.co;2-s10221570
GeRWangZChengLTumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistanceNPJ Precis Oncol.202261311:CAS:528:DC%2BB38Xhs1GhsbzP10.1038/s41698-022-00272-w355086969068628
AmbrosiniVNanniCZompatoriM(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumoursEur J Nucl Med Mol Imaging201037472272710.1007/s00259-009-1349-920107793
AllenFJVan VeldenDJHeynsCFAre neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer?Br J Urol19957567517541:STN:280:DyaK2MzjvVGlsw%3D%3D10.1111/j.1464-410x.1995.tb07385.x7613832
JeetleSSFisherGYangZHNeuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancerVirchows Arch201246121031071:CAS:528:DC%2BC38Xht1egtrfM10.1007/s00428-012-1259-222767265
FurtadoPLimaMVNogueiraCFrancoMTavoraFReview of small cell carcinomas of the prostateProstate Cancer.201120115432721:CAS:528:DC%2BC3MXhtFCkt7fE10.1155/2011/543272221109883200299
FindaklyDWangJMisdiagnosis of small cell prostate cancer: lessons learnedCureus.2020125e835610.7759/cureus.8356324945497263708
ZhouXLiYJiangXIntra-individual comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the evaluation of patients with prostate cancerFront Oncol.20211058521310.3389/fonc.2020.585213336042857884904
CrawfordEDEisenbergerMAMcLeodDGA controlled trial of leuprolide with and without flutamide in prostatic carcinoma [published correction appears in N Engl J Med 1989 Nov 16;321(20):1420]N Engl J Med198932174194241:STN:280:DyaL1MzksVWgtw%3D%3D10.1056/NEJM1989081732107022503724
BeltranHRickmanDSParkKMolecular characterization of neuroendocrine prostate cancer and identification of new drug targetsCancer Discov2011164874951:CAS:528:DC%2BC3MXhsVOhtbfJ10.1158/2159-8290.CD-11-0130223898703290518
SprattDEGavaneSTarlintonLUtility of FDG-PET in clinical neuroendocrine prostate cancerProstate20147411115311591:CAS:528:DC%2BC2cXhtVSqtLjE10.1002/pros.22831249139884355960
BinderupTKniggeULoftAFederspielBKjaerA18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumorsClin Cancer Res20101639789851:CAS:528:DC%2BC3cXhs1aqs7k%3D10.1158/1078-0432.CCR-09-175920103666
ParidaGKTripathySDatta GuptaSAdenocarcinoma prostate with neuroendocrine differentiation: potential utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT over 68Ga-PSMA PET/CTClin Nucl Med201843424824910.1097/RLU.000000000000201329474196
BeyerTTownsendDWBrunTA combined PET/CT scanner for clinical oncologyJ Nucl Med2000418136913791:STN:280:DC%2BD3cvitFCguw%3D%3D10945530
HopeTAGoodmanJZAllenIECalaisJFendlerWPCarrollPRMetaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathologyJ Nucl Med20196067867931:CAS:528:DC%2BB3cXpslarsg%3D%3D10.2967/jnumed.118.219501305308316581235
JadvarHImaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitationsEur J Nucl Med Mol Imaging.201340015101:CAS:528:DC%2BC3sXpvFeisrk%3D10.1007/s00259-013-2361-73681838
RosarFRibbatKRiesMNeuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patientsEJNMMI Res.2020101521:CAS:528:DC%2BB3cXhtVemu7fL10.1186/s13550-020-00640-2324490867246282
McClintockJSpeightsVOJrNeuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progressionCancer19947471899190310.1002/1097-0142(19941001)74:7<1899::aid-cncr2820740712>3.0.co;2-u8082095
SalminenEHoggABinnsDFrydenbergMHicksRInvestigations with FDG-PET scanning in prostate cancer show limited value for clinical practiceActa Oncol200241542542910.1080/02841860232040500512442917
MerkensLSailerVLesselDAggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiationJ Exp Clin Cancer Res.2022411461:CAS:528:DC%2BB38XhtVeisLfL10.1186/s13046-022-02255-y351098998808994
DeorahSRaoMBRamanRGaitondeKDonovanJFSurvival of patients with small cell carcinoma of the prostate during 1973–2003: a population-based studyBJU Int2012109682483010.1111/j.1464-410X.2011.10523.x21883857
LenganaTLawalIOBoshomaneTG68Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli?Clin Genitourin Cancer201816539240110.1016/j.clgc.2018.07.00930120038
TanMOKaraoğlanUCelikBAtaoğluOBiriHBozkirliIProstate cancer and neuroendocrine differentiationInt Urol Nephrol199931175821:STN:280:DyaK1MzjsVOqsw%3D%3D10.1023/a:100717592408210408306
FendlerWPCalaisJEiberMAssessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trialJAMA Oncol20195685686310.1001/jamaoncol.2019.0096309205936567829
Bar-ShalomRYefremovNGuralnikLClinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient managementJ Nucl Med20034481200120912902408
UsmaniSAhmedNMarafiFRasheedRAmangunoHGAlKFMolecular imaging in neuroendocrine differentiation of prostate cancer: 68Ga-PSMA versus 68Ga-DOTA NOC PET-CTClin Nucl Med201742541041310.1097/RLU.000000000000161828240661
BradleyJDDehdashtiFMintunMAGovindanRTrinkausKSiegelBAPositron emission tomography in limited-stage small-cell lung cancer: a prospective studyJ Clin Oncol200422163248325410.1200/JCO.2004.11.08915310768
SartorODe BonoJChiKNFizaziKHerrmannKRahbarKTagawaSTNordquistLTVaishampayanNEl-HaddadGParkCHLutetium-177–PSMA-617 for metastatic castration-resistant prostate cancerN Engl J Med202138512109111031:CAS:528:DC%2BB3MXitVCktLjF10.1056/NEJMoa2107322341610518446332
PereraMPapaNRobertsMGallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysisEur Urol202077440341710.1016/j.eururo.2019.01.04930773328
ScherHIHalabiSTannockIDesign and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupJ Clin Oncol20082671148115910.1200/JCO.2007.12.448718309951
Shah RB, Zhou M. Histologic variants of acinar adenocarcinoma, ductal adenocarcinoma, neuroendocrine tumors, and other carcinomas. In: Prostate Biopsy Interpretation 2019 (pp. 69–95). Springer, Cham
ParkerCCastroEFizaziKHeidenreichAOstPProcopioGTombalBGillessenSProstate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol2020319111911341:STN:280:DC%2BB38nlsVahsA%3D%3D10.1016/j.annonc.2020.06.01132593798
ConteducaVScarpiESalviSPlasma androgen receptor and serum chromogranin A in advanced prostate cancerSci Rep.201881154421:CAS:528:DC%2BC1MXhtFWmtb0%3D10.1038/s41598-018-33774-4303375896194135
ParimiVGoyalRPoropatichKYangXJNeuroendocrine differentiation of prostate cancer: a reviewAm J Clin Exp Urol.20142427385256065734297323
TuXChangTNieLLarge cell neuroendocrine carcinoma of the prostate: a systematic review and pooled analysisUrol Int2019103438339010.1159/00049988330965328
AkamatsuSInoueTOgawaOGleaveMEClinical and molecular features of treatment-related neuroendocrine prostate cancerInt J Urol20182543453511:CAS:528:DC%2BC1cXnvFaksb0%3D10.1111/iju.1352629396873
HofmanMSLawrentschukNFrancisRJProstate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyLancet202039510231120812161:CAS:528:DC%2BB3cXlsFegsr4%3D10.1016/S0140-6736(20)30314-732209449
HuJHanBHuangJMorphologic spectrum of neuroendocrine tumors of the prostate: an updated reviewArch Pathol Lab Med202014433203251:CAS:528:DC%2BB3cXhtlOku7vP10.5858/arpa.2019-0434-RA31644322
WangWEpsteinJISmall cell carcinoma of the prostate. A morpholo
MS Hofman (9619_CR17) 2015; 35
X Tu (9619_CR74) 2019; 103
JR Strosberg (9619_CR83) 2021; 22
L Merkens (9619_CR7) 2022; 41
V Conteduca (9619_CR29) 2018; 8
G Savelli (9619_CR49) 2015; 3
DM Marcus (9619_CR66) 2012; 15
B Goulet-Salmon (9619_CR77) 2004; 27
SS Jeetle (9619_CR62) 2012; 461
I Kayani (9619_CR15) 2008; 112
Y Liu (9619_CR46) 2008; 6
K Shen (9619_CR48) 2021; 11
JE Berchuck (9619_CR64) 2021; 24
C Parker (9619_CR4) 2020; 31
S Usmani (9619_CR52) 2017; 42
J McClintock (9619_CR61) 1994; 74
E Panagiotidis (9619_CR16) 2017; 58
MS Hofman (9619_CR19) 2018; 38
ON Gofrit (9619_CR50) 2017; 42
W Sleiman (9619_CR73) 2021; 15
T Beyer (9619_CR12) 2000; 41
MS Hofman (9619_CR34) 2020; 395
H Beltran (9619_CR24) 2011; 1
FJ Allen (9619_CR59) 1995; 75
M Perera (9619_CR37) 2020; 77
T Binderup (9619_CR72) 2010; 16
KL Wallitt (9619_CR40) 2017; 37
R Casella (9619_CR58) 1998; 160
G Savelli (9619_CR51) 2014; 5
S Deorah (9619_CR65) 2012; 109
X Zhou (9619_CR39) 2021; 10
F Labrie (9619_CR21) 1982; 5
J Vargas Ahumada (9619_CR44) 2022; 12
N Vashchenko (9619_CR56) 2005; 47
RA Simon (9619_CR70) 2009; 40
O Sartor (9619_CR33) 2021; 385
GK Parida (9619_CR43) 2018; 43
S Terry (9619_CR25) 2014; 4
J Hu (9619_CR53) 2020; 144
R Bar-Shalom (9619_CR11) 2003; 44
H Jadvar (9619_CR14) 2013; 40
9619_CR1
P Furtado (9619_CR68) 2011; 2011
9619_CR2
M Gabriel (9619_CR81) 2007; 48
JI Epstein (9619_CR54) 2014; 38
B Shaygan (9619_CR18) 2021; 15
SW Fine (9619_CR10) 2018; 31
S Akamatsu (9619_CR31) 2018; 25
AJ Evans (9619_CR75) 2006; 30
D Putzer (9619_CR82) 2009; 50
W Wang (9619_CR67) 2008; 32
R Ge (9619_CR6) 2022; 6
V Parimi (9619_CR8) 2014; 2
MK Bakht (9619_CR42) 2018; 26
W Luboldt (9619_CR41) 2010; 12
F Rosar (9619_CR47) 2020; 10
J Morote (9619_CR27) 2022; 10
Y Yamada (9619_CR28) 2021; 23
T Szarvas (9619_CR30) 2021; 127
T Whelan (9619_CR78) 1995; 153
HI Scher (9619_CR26) 2008; 26
PA Humphrey (9619_CR76) 2012; 60
C Huggins (9619_CR20) 2002; 167
NR Mucci (9619_CR57) 2000; 31
PA Humphrey (9619_CR3) 2016; 70
M Bungaro (9619_CR23) 2020; 3
E Salminen (9619_CR13) 2002; 41
DE Spratt (9619_CR45) 2014; 74
JD Bradley (9619_CR71) 2004; 22
MO Tan (9619_CR60) 1999; 31
ED Crawford (9619_CR22) 1989; 321
T Uo (9619_CR5) 2020; 10
S Alanee (9619_CR32) 2015; 35
PA Abrahamsson (9619_CR63) 1998; 8
DS Priemer (9619_CR9) 2016; 27
D Findakly (9619_CR69) 2020; 12
S Fanti (9619_CR79) 2008; 62
WP Fendler (9619_CR35) 2019; 5
PA Abrahamsson (9619_CR55) 1999; 39
T Lengana (9619_CR38) 2018; 16
V Ambrosini (9619_CR80) 2010; 37
TA Hope (9619_CR36) 2019; 60
References_xml – reference: KayaniIBomanjiJBGrovesAFunctional imaging of neuroendocrine tumors with combined PET/CT using 68Ga-DOTATATE (DOTA-DPhe1, Tyr3-octreotate) and 18F-FDGCancer2008112112447245510.1002/cncr.2346918383518
– reference: HopeTAGoodmanJZAllenIECalaisJFendlerWPCarrollPRMetaanalysis of 68Ga-PSMA-11 PET accuracy for the detection of prostate cancer validated by histopathologyJ Nucl Med20196067867931:CAS:528:DC%2BB3cXpslarsg%3D%3D10.2967/jnumed.118.219501305308316581235
– reference: UsmaniSAhmedNMarafiFRasheedRAmangunoHGAlKFMolecular imaging in neuroendocrine differentiation of prostate cancer: 68Ga-PSMA versus 68Ga-DOTA NOC PET-CTClin Nucl Med201742541041310.1097/RLU.000000000000161828240661
– reference: ScherHIHalabiSTannockIDesign and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working GroupJ Clin Oncol20082671148115910.1200/JCO.2007.12.448718309951
– reference: LiuYFDG PET-CT demonstration of metastatic neuroendocrine tumor of prostateWorld J Surg Oncol.200866410.1186/1477-7819-6-64185652312440384
– reference: CasellaRBubendorfLSauterGMochHMihatschMJGasserTCFocal neuroendocrine differentiation lacks prognostic significance in prostate core needle biopsiesJ Urol199816024064101:STN:280:DyaK1czktlCrsA%3D%3D10.1016/S0022-5347(01)62909-49679888
– reference: ParkerCCastroEFizaziKHeidenreichAOstPProcopioGTombalBGillessenSProstate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol2020319111911341:STN:280:DC%2BB38nlsVahsA%3D%3D10.1016/j.annonc.2020.06.01132593798
– reference: FantiSAmbrosiniVTomassettiPEvaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PETBiomed Pharmacother200862106676711:CAS:528:DC%2BD1cXhtlyksL3K10.1016/j.biopha.2008.01.01018358680
– reference: HofmanMSLawrentschukNFrancisRJProstate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre studyLancet202039510231120812161:CAS:528:DC%2BB3cXlsFegsr4%3D10.1016/S0140-6736(20)30314-732209449
– reference: PereraMPapaNRobertsMGallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysisEur Urol202077440341710.1016/j.eururo.2019.01.04930773328
– reference: ZhouXLiYJiangXIntra-individual comparison of 18F-PSMA-1007 and 18F-FDG PET/CT in the evaluation of patients with prostate cancerFront Oncol.20211058521310.3389/fonc.2020.585213336042857884904
– reference: AbrahamssonPACockettATdi Sant'AgnesePAPrognostic significance of neuroendocrine differentiation in clinically localized prostatic carcinomaProstate Suppl1998837421:STN:280:DyaK1czlt12ksA%3D%3D10.1002/(SICI)1097-0045(1998)8+<37::AID-PROS7>3.0.CO;2-D9690662
– reference: WangWEpsteinJISmall cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 casesAm J Surg Pathol.2008321657110.1097/PAS.0b013e318058a96b18162772
– reference: SartorODe BonoJChiKNFizaziKHerrmannKRahbarKTagawaSTNordquistLTVaishampayanNEl-HaddadGParkCHLutetium-177–PSMA-617 for metastatic castration-resistant prostate cancerN Engl J Med202138512109111031:CAS:528:DC%2BB3MXitVCktLjF10.1056/NEJMoa2107322341610518446332
– reference: EpsteinJIAminMBBeltranHProposed morphologic classification of prostate cancer with neuroendocrine differentiationAm J Surg Pathol201438675676710.1097/PAS.0000000000000208247053114112087
– reference: AlaneeSMooreANuttMContemporary incidence and mortality rates of neuroendocrine prostate cancerAnticancer Res20153574145415026124369
– reference: Bar-ShalomRYefremovNGuralnikLClinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient managementJ Nucl Med20034481200120912902408
– reference: LuboldtWZöphelKWunderlichGAbramyukALuboldtHJKotzerkeJVisualization of somatostatin receptors in prostate cancer and its bone metastases with Ga-68-DOTATOC PET/CTMol Imaging Biol2010121788410.1007/s11307-009-0230-319421819
– reference: PriemerDSMontironiRWangLWilliamsonSRLopez-BeltranAChengLNeuroendocrine tumors of the prostate: emerging insights from molecular data and updates to the 2016 World Health Organization ClassificationEndocr Pathol20162721231351:CAS:528:DC%2BC28XjtFKrs7w%3D10.1007/s12022-016-9421-z26885643
– reference: CrawfordEDEisenbergerMAMcLeodDGA controlled trial of leuprolide with and without flutamide in prostatic carcinoma [published correction appears in N Engl J Med 1989 Nov 16;321(20):1420]N Engl J Med198932174194241:STN:280:DyaL1MzksVWgtw%3D%3D10.1056/NEJM1989081732107022503724
– reference: SavelliGMuniAFalchiRSomatostatin receptors over-expression in castration resistant prostate cancer detected by PET/CT: preliminary report of in six patientsAnn Transl Med20153101451:CAS:528:DC%2BC28XhtlOjsbnL10.3978/j.issn.2305-5839.2015.06.10262072384486921
– reference: BeltranHRickmanDSParkKMolecular characterization of neuroendocrine prostate cancer and identification of new drug targetsCancer Discov2011164874951:CAS:528:DC%2BC3MXhsVOhtbfJ10.1158/2159-8290.CD-11-0130223898703290518
– reference: AbrahamssonPANeuroendocrine differentiation in prostatic carcinomaProstate19993921351481:CAS:528:DyaK1MXivF2gtL8%3D10.1002/(sici)1097-0045(19990501)39:2<135::aid-pros9>3.0.co;2-s10221570
– reference: LabrieFDupontABelangerANew hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogenClin Invest Med1982542672751:STN:280:DyaL3s7jtVWhsg%3D%3D6819101
– reference: JadvarHImaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitationsEur J Nucl Med Mol Imaging.201340015101:CAS:528:DC%2BC3sXpvFeisrk%3D10.1007/s00259-013-2361-73681838
– reference: PutzerDGabrielMHenningerBBone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphyJ Nucl Med20095081214122110.2967/jnumed.108.06023619617343
– reference: JeetleSSFisherGYangZHNeuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancerVirchows Arch201246121031071:CAS:528:DC%2BC38Xht1egtrfM10.1007/s00428-012-1259-222767265
– reference: SleimanWKarrayOAbi AbdallahMLarge-cell neuroendocrine tumor of the prostate: a case report and review of the literatureJ Med Case Rep.202115125410.1186/s13256-021-02830-5339579798103761
– reference: MerkensLSailerVLesselDAggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiationJ Exp Clin Cancer Res.2022411461:CAS:528:DC%2BB38XhtVeisLfL10.1186/s13046-022-02255-y351098998808994
– reference: SalminenEHoggABinnsDFrydenbergMHicksRInvestigations with FDG-PET scanning in prostate cancer show limited value for clinical practiceActa Oncol200241542542910.1080/02841860232040500512442917
– reference: YamadaYBeltranHClinical and biological features of neuroendocrine prostate cancerCurr Oncol Rep.20212321510.1007/s11912-020-01003-9334337377990389
– reference: ParidaGKTripathySDatta GuptaSAdenocarcinoma prostate with neuroendocrine differentiation: potential utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT over 68Ga-PSMA PET/CTClin Nucl Med201843424824910.1097/RLU.000000000000201329474196
– reference: SavelliGMuniABarbieriRNeuroendocrine differentiation of prostate cancer metastases evidenced "in Vivo" by 68Ga-DOTANOC PET/CT: two casesWorld J Oncol201452727610.14740/wjon739w291473815649877
– reference: StrosbergJRCaplinMEKunzPLRuszniewskiPBBodeiLHendifarAMittraEWolinEMYaoJCPavelMEGrandeE177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trialLancet Oncol20212212175217631:CAS:528:DC%2BB38XmvVKhsr8%3D10.1016/S1470-2045(21)00572-634793718
– reference: HumphreyPAMochHCubillaALUlbrightTMReuterVEThe 2016 WHO classification of tumours of the urinary system and male genital organs—part B: prostate and bladder tumoursEur Urol201670110611910.1016/j.eururo.2016.02.02826996659
– reference: HofmanMSLauWFHicksRJSomatostatin receptor imaging with 68Ga DOTATATE PET/CT: clinical utility, normal patterns, pearls, and pitfalls in interpretationRadiographics201535250051610.1148/rg.35214016425763733
– reference: UoTSprengerCCPlymateSRAndrogen receptor signaling and metabolic and cellular plasticity during progression to castration resistant prostate cancerFront Oncol.20201058061710.3389/fonc.2020.580617331634097581990
– reference: DeorahSRaoMBRamanRGaitondeKDonovanJFSurvival of patients with small cell carcinoma of the prostate during 1973–2003: a population-based studyBJU Int2012109682483010.1111/j.1464-410X.2011.10523.x21883857
– reference: ShayganBZukotynskiKBénardFCanadian Urological Association best practice report: prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) and PET/magnetic resonance (MR) in prostate [published correction appears in Can Urol Assoc J. 2021 Aug;15(8):E423]Can Urol Assoc J.202115616217210.5489/cuaj.7268336610938195587
– reference: VashchenkoNAbrahamssonPANeuroendocrine differentiation in prostate cancer: implications for new treatment modalitiesEur Urol20054721471551:CAS:528:DC%2BD2MXhslyht7w%3D10.1016/j.eururo.2004.09.00715661408
– reference: Vargas AhumadaJGonzález RuedaSDSinisterra SolísFAMultitarget molecular imaging in metastatic castration resistant adenocarcinoma prostate cancer with therapy induced neuroendocrine differentiationDiagnostics (Basel).2022126138710.3390/diagnostics12061387357411979221809
– reference: GabrielMDecristoforoCKendlerD68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CTJ Nucl Med20074845085181:CAS:528:DC%2BD2sXhtVert7jF10.2967/jnumed.106.03566717401086
– reference: FendlerWPCalaisJEiberMAssessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trialJAMA Oncol20195685686310.1001/jamaoncol.2019.0096309205936567829
– reference: BeyerTTownsendDWBrunTA combined PET/CT scanner for clinical oncologyJ Nucl Med2000418136913791:STN:280:DC%2BD3cvitFCguw%3D%3D10945530
– reference: BungaroMButtiglieroCTucciMOvercoming the mechanisms of primary and acquired resistance to new generation hormonal therapies in advanced prostate cancer: focus on androgen receptor independent pathwaysCancer Drug Resist.202034726411:CAS:528:DC%2BB3MXhslCmsb%2FJ10.20517/cdr.2020.42355822268992570
– reference: American Cancer Society. Cancer facts & figures 2022. Available at https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2022.html. Accessed: September 7, 2022
– reference: GeRWangZChengLTumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistanceNPJ Precis Oncol.202261311:CAS:528:DC%2BB38Xhs1GhsbzP10.1038/s41698-022-00272-w355086969068628
– reference: TuXChangTNieLLarge cell neuroendocrine carcinoma of the prostate: a systematic review and pooled analysisUrol Int2019103438339010.1159/00049988330965328
– reference: HuJHanBHuangJMorphologic spectrum of neuroendocrine tumors of the prostate: an updated reviewArch Pathol Lab Med202014433203251:CAS:528:DC%2BB3cXhtlOku7vP10.5858/arpa.2019-0434-RA31644322
– reference: FindaklyDWangJMisdiagnosis of small cell prostate cancer: lessons learnedCureus.2020125e835610.7759/cureus.8356324945497263708
– reference: PanagiotidisEAlshammariAMichopoulouSComparison of the impact of 68Ga-DOTATATE and 18F-FDG PET/CT on clinical management in patients with neuroendocrine tumorsJ Nucl Med2017581919610.2967/jnumed.116.17809527516446
– reference: LenganaTLawalIOBoshomaneTG68Ga-PSMA PET/CT replacing bone scan in the initial staging of skeletal metastasis in prostate cancer: a fait accompli?Clin Genitourin Cancer201816539240110.1016/j.clgc.2018.07.00930120038
– reference: SimonRAdi Sant'AgnesePAHuangLSCD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickersHum Pathol20094022522581:CAS:528:DC%2BD1MXjvFWisg%3D%3D10.1016/j.humpath.2008.07.01418835619
– reference: EvansAJHumphreyPABelaniJvan der KwastTHSrigleyJRLarge cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancerAm J Surg Pathol200630668469310.1097/00000478-200606000-0000316723845
– reference: TerrySBeltranHThe many faces of neuroendocrine differentiation in prostate cancer progressionFront Oncol.201446010.3389/fonc.2014.00060247240543971158
– reference: MarcusDMGoodmanMJaniABOsunkoyaAORossiPJA comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008Prostate Cancer Prostatic Dis20121532832881:STN:280:DC%2BC38vjs1Wqsg%3D%3D10.1038/pcan.2012.422349984
– reference: HumphreyPAHistological variants of prostatic carcinoma and their significanceHistopathology2012601597410.1111/j.1365-2559.2011.04039.x22212078
– reference: ShenKLiuBZhouXThe evolving role of 18F-FDG PET/CT in diagnosis and prognosis prediction in progressive prostate cancerFront Oncol.2021116837931:CAS:528:DC%2BB3sXht1Ghs7fM10.3389/fonc.2021.683793343952518358601
– reference: AmbrosiniVNanniCZompatoriM(68)Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumoursEur J Nucl Med Mol Imaging201037472272710.1007/s00259-009-1349-920107793
– reference: BakhtMKDerecicheiILiYNeuroendocrine differentiation of prostate cancer leads to PSMA suppressionEndocr Relat Cancer.20182621314610.1530/ERC-18-022630400059
– reference: BradleyJDDehdashtiFMintunMAGovindanRTrinkausKSiegelBAPositron emission tomography in limited-stage small-cell lung cancer: a prospective studyJ Clin Oncol200422163248325410.1200/JCO.2004.11.08915310768
– reference: HugginsCHodgesCVStudies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941J Urol.20021672 Pt 2948521:CAS:528:DC%2BD38XhtVylsbw%3D10.1016/S0022-5347(02)80307-X11905923
– reference: ConteducaVScarpiESalviSPlasma androgen receptor and serum chromogranin A in advanced prostate cancerSci Rep.201881154421:CAS:528:DC%2BC1MXhtFWmtb0%3D10.1038/s41598-018-33774-4303375896194135
– reference: Shah RB, Zhou M. Histologic variants of acinar adenocarcinoma, ductal adenocarcinoma, neuroendocrine tumors, and other carcinomas. In: Prostate Biopsy Interpretation 2019 (pp. 69–95). Springer, Cham
– reference: HofmanMSHicksRJMaurerTEiberMProstate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfallsRadiographics201838120021710.1148/rg.201817010829320333
– reference: AkamatsuSInoueTOgawaOGleaveMEClinical and molecular features of treatment-related neuroendocrine prostate cancerInt J Urol20182543453511:CAS:528:DC%2BC1cXnvFaksb0%3D10.1111/iju.1352629396873
– reference: RosarFRibbatKRiesMNeuron-specific enolase has potential value as a biomarker for [18F]FDG/[68Ga]Ga-PSMA-11 PET mismatch findings in advanced mCRPC patientsEJNMMI Res.2020101521:CAS:528:DC%2BB3cXhtVemu7fL10.1186/s13550-020-00640-2324490867246282
– reference: WallittKLKhanSRDubashSTamHHKhanSBarwickTDClinical PET imaging in prostate cancerRadiographics20173751512153610.1148/rg.201717003528800286
– reference: Goulet-SalmonBBertheEFrancSProstatic neuroendocrine tumor in multiple endocrine neoplasia Type 2BJ Endocrinol Invest20042765705731:STN:280:DC%2BD2M%2Foslyrug%3D%3D10.1007/BF0334748115717656
– reference: WhelanTGatfieldCTRobertsonSCarpenterBSchillingerJFPrimary carcinoid of the prostate in conjunction with multiple endocrine neoplasia IIb in a childJ Urol19951533 Pt 2108010821:STN:280:DyaK2M7ls1KltA%3D%3D7853568
– reference: SprattDEGavaneSTarlintonLUtility of FDG-PET in clinical neuroendocrine prostate cancerProstate20147411115311591:CAS:528:DC%2BC2cXhtVSqtLjE10.1002/pros.22831249139884355960
– reference: AllenFJVan VeldenDJHeynsCFAre neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer?Br J Urol19957567517541:STN:280:DyaK2MzjvVGlsw%3D%3D10.1111/j.1464-410x.1995.tb07385.x7613832
– reference: MoroteJAguilarAPlanasJTrillaEDefinition of castrate resistant prostate cancer: new insightsBiomedicines.20221036891:CAS:528:DC%2BB38XosVOltb4%3D10.3390/biomedicines10030689353274918945091
– reference: MucciNRAkdasGManelySRubinMANeuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression [published correction appears in Hum Pathol 2000 Jun; 31(6):778]Hum Pathol20003144064141:CAS:528:DC%2BD3cXjsFCgtLc%3D10.1053/hp.2000.729510821485
– reference: BerchuckJEViscusePVBeltranHAparicioAClinical considerations for the management of androgen indifferent prostate cancerProstate Cancer Prostatic Dis202124362363710.1038/s41391-021-00332-5335687488353003
– reference: ParimiVGoyalRPoropatichKYangXJNeuroendocrine differentiation of prostate cancer: a reviewAm J Clin Exp Urol.20142427385256065734297323
– reference: TanMOKaraoğlanUCelikBAtaoğluOBiriHBozkirliIProstate cancer and neuroendocrine differentiationInt Urol Nephrol199931175821:STN:280:DyaK1MzjsVOqsw%3D%3D10.1023/a:100717592408210408306
– reference: GofritONFrankSMeirovitzANechushtanHOreviMPET/CT With 68Ga-DOTA-TATE for diagnosis of neuroendocrine: differentiation in patients with castrate-resistant prostate cancerClin Nucl Med20174211610.1097/RLU.000000000000142427775942
– reference: FurtadoPLimaMVNogueiraCFrancoMTavoraFReview of small cell carcinomas of the prostateProstate Cancer.201120115432721:CAS:528:DC%2BC3MXhtFCkt7fE10.1155/2011/543272221109883200299
– reference: McClintockJSpeightsVOJrNeuroendocrine differentiation in prostatic adenocarcinoma and its relationship to tumor progressionCancer19947471899190310.1002/1097-0142(19941001)74:7<1899::aid-cncr2820740712>3.0.co;2-u8082095
– reference: BinderupTKniggeULoftAFederspielBKjaerA18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumorsClin Cancer Res20101639789851:CAS:528:DC%2BC3cXhs1aqs7k%3D10.1158/1078-0432.CCR-09-175920103666
– reference: SzarvasTCsizmarikAFazekasTComprehensive analysis of serum chromogranin A and neuron-specific enolase levels in localized and castration-resistant prostate cancerBJU Int2021127144551:CAS:528:DC%2BB3MXmtl2ruw%3D%3D10.1111/bju.1508632314509
– reference: FineSWNeuroendocrine tumors of the prostateMod Pathol201831S112213210.1038/modpathol.2017.164
– volume: 31
  start-page: 406
  issue: 4
  year: 2000
  ident: 9619_CR57
  publication-title: Hum Pathol
  doi: 10.1053/hp.2000.7295
– volume: 43
  start-page: 248
  issue: 4
  year: 2018
  ident: 9619_CR43
  publication-title: Clin Nucl Med
  doi: 10.1097/RLU.0000000000002013
– volume: 25
  start-page: 345
  issue: 4
  year: 2018
  ident: 9619_CR31
  publication-title: Int J Urol
  doi: 10.1111/iju.13526
– volume: 10
  start-page: 689
  issue: 3
  year: 2022
  ident: 9619_CR27
  publication-title: Biomedicines.
  doi: 10.3390/biomedicines10030689
– volume: 15
  start-page: 162
  issue: 6
  year: 2021
  ident: 9619_CR18
  publication-title: Can Urol Assoc J.
  doi: 10.5489/cuaj.7268
– ident: 9619_CR1
– volume: 10
  start-page: 52
  issue: 1
  year: 2020
  ident: 9619_CR47
  publication-title: EJNMMI Res.
  doi: 10.1186/s13550-020-00640-2
– volume: 5
  start-page: 72
  issue: 2
  year: 2014
  ident: 9619_CR51
  publication-title: World J Oncol
  doi: 10.14740/wjon739w
– volume: 75
  start-page: 751
  issue: 6
  year: 1995
  ident: 9619_CR59
  publication-title: Br J Urol
  doi: 10.1111/j.1464-410x.1995.tb07385.x
– volume: 40
  start-page: 5
  issue: 01
  year: 2013
  ident: 9619_CR14
  publication-title: Eur J Nucl Med Mol Imaging.
  doi: 10.1007/s00259-013-2361-7
– volume: 144
  start-page: 320
  issue: 3
  year: 2020
  ident: 9619_CR53
  publication-title: Arch Pathol Lab Med
  doi: 10.5858/arpa.2019-0434-RA
– volume: 41
  start-page: 425
  issue: 5
  year: 2002
  ident: 9619_CR13
  publication-title: Acta Oncol
  doi: 10.1080/028418602320405005
– volume: 11
  start-page: 683793
  year: 2021
  ident: 9619_CR48
  publication-title: Front Oncol.
  doi: 10.3389/fonc.2021.683793
– volume: 47
  start-page: 147
  issue: 2
  year: 2005
  ident: 9619_CR56
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2004.09.007
– volume: 58
  start-page: 91
  issue: 1
  year: 2017
  ident: 9619_CR16
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.116.178095
– volume: 42
  start-page: 410
  issue: 5
  year: 2017
  ident: 9619_CR52
  publication-title: Clin Nucl Med
  doi: 10.1097/RLU.0000000000001618
– volume: 385
  start-page: 1091
  issue: 12
  year: 2021
  ident: 9619_CR33
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa2107322
– volume: 15
  start-page: 283
  issue: 3
  year: 2012
  ident: 9619_CR66
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/pcan.2012.4
– volume: 127
  start-page: 44
  issue: 1
  year: 2021
  ident: 9619_CR30
  publication-title: BJU Int
  doi: 10.1111/bju.15086
– ident: 9619_CR2
  doi: 10.1007/978-3-030-13601-7_6
– volume: 2
  start-page: 273
  issue: 4
  year: 2014
  ident: 9619_CR8
  publication-title: Am J Clin Exp Urol.
– volume: 31
  start-page: 75
  issue: 1
  year: 1999
  ident: 9619_CR60
  publication-title: Int Urol Nephrol
  doi: 10.1023/a:1007175924082
– volume: 12
  start-page: e8356
  issue: 5
  year: 2020
  ident: 9619_CR69
  publication-title: Cureus.
  doi: 10.7759/cureus.8356
– volume: 15
  start-page: 254
  issue: 1
  year: 2021
  ident: 9619_CR73
  publication-title: J Med Case Rep.
  doi: 10.1186/s13256-021-02830-5
– volume: 5
  start-page: 267
  issue: 4
  year: 1982
  ident: 9619_CR21
  publication-title: Clin Invest Med
– volume: 23
  start-page: 15
  issue: 2
  year: 2021
  ident: 9619_CR28
  publication-title: Curr Oncol Rep.
  doi: 10.1007/s11912-020-01003-9
– volume: 10
  start-page: 580617
  year: 2020
  ident: 9619_CR5
  publication-title: Front Oncol.
  doi: 10.3389/fonc.2020.580617
– volume: 3
  start-page: 145
  issue: 10
  year: 2015
  ident: 9619_CR49
  publication-title: Ann Transl Med
  doi: 10.3978/j.issn.2305-5839.2015.06.10
– volume: 8
  start-page: 15442
  issue: 1
  year: 2018
  ident: 9619_CR29
  publication-title: Sci Rep.
  doi: 10.1038/s41598-018-33774-4
– volume: 6
  start-page: 64
  year: 2008
  ident: 9619_CR46
  publication-title: World J Surg Oncol.
  doi: 10.1186/1477-7819-6-64
– volume: 38
  start-page: 756
  issue: 6
  year: 2014
  ident: 9619_CR54
  publication-title: Am J Surg Pathol
  doi: 10.1097/PAS.0000000000000208
– volume: 26
  start-page: 131
  issue: 2
  year: 2018
  ident: 9619_CR42
  publication-title: Endocr Relat Cancer.
  doi: 10.1530/ERC-18-0226
– volume: 167
  start-page: 948
  issue: 2 Pt 2
  year: 2002
  ident: 9619_CR20
  publication-title: J Urol.
  doi: 10.1016/S0022-5347(02)80307-X
– volume: 395
  start-page: 1208
  issue: 10231
  year: 2020
  ident: 9619_CR34
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30314-7
– volume: 35
  start-page: 500
  issue: 2
  year: 2015
  ident: 9619_CR17
  publication-title: Radiographics
  doi: 10.1148/rg.352140164
– volume: 44
  start-page: 1200
  issue: 8
  year: 2003
  ident: 9619_CR11
  publication-title: J Nucl Med
– volume: 37
  start-page: 1512
  issue: 5
  year: 2017
  ident: 9619_CR40
  publication-title: Radiographics
  doi: 10.1148/rg.2017170035
– volume: 26
  start-page: 1148
  issue: 7
  year: 2008
  ident: 9619_CR26
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2007.12.4487
– volume: 42
  start-page: 1
  issue: 1
  year: 2017
  ident: 9619_CR50
  publication-title: Clin Nucl Med
  doi: 10.1097/RLU.0000000000001424
– volume: 22
  start-page: 1752
  issue: 12
  year: 2021
  ident: 9619_CR83
  publication-title: Lancet Oncol
  doi: 10.1016/S1470-2045(21)00572-6
– volume: 5
  start-page: 856
  issue: 6
  year: 2019
  ident: 9619_CR35
  publication-title: JAMA Oncol
  doi: 10.1001/jamaoncol.2019.0096
– volume: 8
  start-page: 37
  year: 1998
  ident: 9619_CR63
  publication-title: Prostate Suppl
  doi: 10.1002/(SICI)1097-0045(1998)8+<37::AID-PROS7>3.0.CO;2-D
– volume: 41
  start-page: 46
  issue: 1
  year: 2022
  ident: 9619_CR7
  publication-title: J Exp Clin Cancer Res.
  doi: 10.1186/s13046-022-02255-y
– volume: 27
  start-page: 123
  issue: 2
  year: 2016
  ident: 9619_CR9
  publication-title: Endocr Pathol
  doi: 10.1007/s12022-016-9421-z
– volume: 38
  start-page: 200
  issue: 1
  year: 2018
  ident: 9619_CR19
  publication-title: Radiographics
  doi: 10.1148/rg.2018170108
– volume: 6
  start-page: 31
  issue: 1
  year: 2022
  ident: 9619_CR6
  publication-title: NPJ Precis Oncol.
  doi: 10.1038/s41698-022-00272-w
– volume: 39
  start-page: 135
  issue: 2
  year: 1999
  ident: 9619_CR55
  publication-title: Prostate
  doi: 10.1002/(sici)1097-0045(19990501)39:2<135::aid-pros9>3.0.co;2-s
– volume: 31
  start-page: 122
  issue: S1
  year: 2018
  ident: 9619_CR10
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2017.164
– volume: 60
  start-page: 59
  issue: 1
  year: 2012
  ident: 9619_CR76
  publication-title: Histopathology
  doi: 10.1111/j.1365-2559.2011.04039.x
– volume: 16
  start-page: 392
  issue: 5
  year: 2018
  ident: 9619_CR38
  publication-title: Clin Genitourin Cancer
  doi: 10.1016/j.clgc.2018.07.009
– volume: 22
  start-page: 3248
  issue: 16
  year: 2004
  ident: 9619_CR71
  publication-title: J Clin Oncol
  doi: 10.1200/JCO.2004.11.089
– volume: 16
  start-page: 978
  issue: 3
  year: 2010
  ident: 9619_CR72
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-09-1759
– volume: 4
  start-page: 60
  year: 2014
  ident: 9619_CR25
  publication-title: Front Oncol.
  doi: 10.3389/fonc.2014.00060
– volume: 1
  start-page: 487
  issue: 6
  year: 2011
  ident: 9619_CR24
  publication-title: Cancer Discov
  doi: 10.1158/2159-8290.CD-11-0130
– volume: 60
  start-page: 786
  issue: 6
  year: 2019
  ident: 9619_CR36
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.118.219501
– volume: 37
  start-page: 722
  issue: 4
  year: 2010
  ident: 9619_CR80
  publication-title: Eur J Nucl Med Mol Imaging
  doi: 10.1007/s00259-009-1349-9
– volume: 2011
  start-page: 543272
  year: 2011
  ident: 9619_CR68
  publication-title: Prostate Cancer.
  doi: 10.1155/2011/543272
– volume: 3
  start-page: 726
  issue: 4
  year: 2020
  ident: 9619_CR23
  publication-title: Cancer Drug Resist.
  doi: 10.20517/cdr.2020.42
– volume: 62
  start-page: 667
  issue: 10
  year: 2008
  ident: 9619_CR79
  publication-title: Biomed Pharmacother
  doi: 10.1016/j.biopha.2008.01.010
– volume: 48
  start-page: 508
  issue: 4
  year: 2007
  ident: 9619_CR81
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.106.035667
– volume: 112
  start-page: 2447
  issue: 11
  year: 2008
  ident: 9619_CR15
  publication-title: Cancer
  doi: 10.1002/cncr.23469
– volume: 74
  start-page: 1899
  issue: 7
  year: 1994
  ident: 9619_CR61
  publication-title: Cancer
  doi: 10.1002/1097-0142(19941001)74:7<1899::aid-cncr2820740712>3.0.co;2-u
– volume: 35
  start-page: 4145
  issue: 7
  year: 2015
  ident: 9619_CR32
  publication-title: Anticancer Res
– volume: 74
  start-page: 1153
  issue: 11
  year: 2014
  ident: 9619_CR45
  publication-title: Prostate
  doi: 10.1002/pros.22831
– volume: 41
  start-page: 1369
  issue: 8
  year: 2000
  ident: 9619_CR12
  publication-title: J Nucl Med
– volume: 12
  start-page: 1387
  issue: 6
  year: 2022
  ident: 9619_CR44
  publication-title: Diagnostics (Basel).
  doi: 10.3390/diagnostics12061387
– volume: 31
  start-page: 1119
  issue: 9
  year: 2020
  ident: 9619_CR4
  publication-title: Ann Oncol
  doi: 10.1016/j.annonc.2020.06.011
– volume: 109
  start-page: 824
  issue: 6
  year: 2012
  ident: 9619_CR65
  publication-title: BJU Int
  doi: 10.1111/j.1464-410X.2011.10523.x
– volume: 40
  start-page: 252
  issue: 2
  year: 2009
  ident: 9619_CR70
  publication-title: Hum Pathol
  doi: 10.1016/j.humpath.2008.07.014
– volume: 321
  start-page: 419
  issue: 7
  year: 1989
  ident: 9619_CR22
  publication-title: N Engl J Med
  doi: 10.1056/NEJM198908173210702
– volume: 153
  start-page: 1080
  issue: 3 Pt 2
  year: 1995
  ident: 9619_CR78
  publication-title: J Urol
– volume: 70
  start-page: 106
  issue: 1
  year: 2016
  ident: 9619_CR3
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2016.02.028
– volume: 103
  start-page: 383
  issue: 4
  year: 2019
  ident: 9619_CR74
  publication-title: Urol Int
  doi: 10.1159/000499883
– volume: 10
  start-page: 585213
  year: 2021
  ident: 9619_CR39
  publication-title: Front Oncol.
  doi: 10.3389/fonc.2020.585213
– volume: 27
  start-page: 570
  issue: 6
  year: 2004
  ident: 9619_CR77
  publication-title: J Endocrinol Invest
  doi: 10.1007/BF03347481
– volume: 461
  start-page: 103
  issue: 2
  year: 2012
  ident: 9619_CR62
  publication-title: Virchows Arch
  doi: 10.1007/s00428-012-1259-2
– volume: 50
  start-page: 1214
  issue: 8
  year: 2009
  ident: 9619_CR82
  publication-title: J Nucl Med
  doi: 10.2967/jnumed.108.060236
– volume: 160
  start-page: 406
  issue: 2
  year: 1998
  ident: 9619_CR58
  publication-title: J Urol
  doi: 10.1016/S0022-5347(01)62909-4
– volume: 24
  start-page: 623
  issue: 3
  year: 2021
  ident: 9619_CR64
  publication-title: Prostate Cancer Prostatic Dis
  doi: 10.1038/s41391-021-00332-5
– volume: 30
  start-page: 684
  issue: 6
  year: 2006
  ident: 9619_CR75
  publication-title: Am J Surg Pathol
  doi: 10.1097/00000478-200606000-00003
– volume: 77
  start-page: 403
  issue: 4
  year: 2020
  ident: 9619_CR37
  publication-title: Eur Urol
  doi: 10.1016/j.eururo.2019.01.049
– volume: 12
  start-page: 78
  issue: 1
  year: 2010
  ident: 9619_CR41
  publication-title: Mol Imaging Biol
  doi: 10.1007/s11307-009-0230-3
– volume: 32
  start-page: 65
  issue: 1
  year: 2008
  ident: 9619_CR67
  publication-title: Am J Surg Pathol.
  doi: 10.1097/PAS.0b013e318058a96b
SSID ssj0009147
Score 2.4310124
SecondaryResourceType review_article
Snippet Prostatic neuroendocrine malignancies represent a spectrum of diseases. Treatment-induced neuroendocrine differentiation (tiNED) in hormonally treated...
SourceID proquest
pubmed
crossref
springer
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 6502
SubjectTerms Adenocarcinoma
Adenocarcinoma - diagnostic imaging
Antigens
Diagnostic Radiology
Differential diagnosis
Differentiation
Fluorine isotopes
Fluorodeoxyglucose F18
Gallium isotopes
Gallium Radioisotopes
Glucose metabolism
Health services
Humans
Imaging
Internal Medicine
Interventional Radiology
Isotopes
Ligands
Male
Malignancy
Medical imaging
Medicine
Medicine & Public Health
Molecular Imaging
Neuroendocrine tumors
Neuroradiology
Nuclear medicine
Positron emission
Positron emission tomography
Positron Emission Tomography Computed Tomography - methods
Prostate - pathology
Prostate cancer
Prostatic Neoplasms - pathology
Radioactive tracers
Radiology
Review
Somatostatin
Tumors
Ultrasound
SummonAdditionalLinks – databaseName: SpringerLINK - Czech Republic Consortium
  dbid: AGYKE
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bS-QwFA6uwrIv3tbLeCOCbxpJm7RNHkVGRVF8cECfSnOTQaeVmY7L7q_fk97EK_jUh1yaJic9Xzg534fQns4iJTRzBJ6c8MhxIrWQxNHIJBn4c8t8vvPlVXw24Oe30W2TFDZpb7u3IcnqT90lu3nZMUrAxxAvUyKJ-IHmIjigwHacOzq9u-i_kO0GPGkSZD5u-doJvUOW76KilbM5WUCDdpj1HZOHw2mpDvW_NwyO3_2ORTTfoE98VJvLEpqx-TL6ednE138jdd2_wePMDItynGlAhhgwLf7jNXSJKsxfPMzx8_C5wKNWVRcPR5XOES4cfvIZJJ4BFlcsmTY3hfbJhXgEYP--1gGerKDBSf_m-Iw0KgxEsyQqCUAiw8LECQuuX2plM0dVoEIeCyUDQbnRceK4pNRoYUIruWRWeFzmWKi5YatoNi9yu46wj5LGNlCBlBnPlIPenDEJFSaBgzIVPRS0y5LqhqLcK2U8ph25cjV5KUxeWk1eCm32uzZPNUHHl7W32tVOm806ScFDi0hIHrMe2u2KYZv52EmW22Lq69TZplL20FptJd3rWOJJcyIoOWhX_KXzz8ey8b3qm-hXWBsNocEWmi3HU7sNgKhUO439_weI3QEc
  priority: 102
  providerName: Springer Nature
Title PET radiotracers for whole-body in vivo molecular imaging of prostatic neuroendocrine malignancies
URI https://link.springer.com/article/10.1007/s00330-023-09619-8
https://www.ncbi.nlm.nih.gov/pubmed/37052659
https://www.proquest.com/docview/2848589463
https://www.proquest.com/docview/2800628599
Volume 33
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dixMxEA_eHYgv4rfVs0TwTYPZTXaTPEkr7R3KlUOuUJ-WzZcU7G5teyf-906y2RY5vKc85GPDTJL5JbMzP4TembrQ0jBPoOSEF54TZaQinhZW1GDPHQvxzhez8nzOvyyKRXpw26bfKvszMR7UtjXhjfwjHKOykIqX7NP6FwmsUcG7mig0jtBJloOtDZHi07ND0t0sEozBpV0SoRRPQTMxdC6QmFECFosE0hNF5L-G6RbavOUpjQZo-gg9TMgRjzpVP0b3XPME3b9IvvGnSF9OrvCmtst2t6kNoDoMeBT_Dvy3RLf2D142-GZ50-JVz4iLl6vIUYRbj9ch-iNkb8Uxw6VrQCIhMBCvAKj_6Dh8t8_QfDq5-nxOEoMCMUwUOwJwxrJceOnAbCujXe2pznTOS6lVJim3phSeK0qtkTZ3iivmZMBUnuWGW_YcHTdt414iHDycpct0plTNa-1hNG-toNIKuORSOUBZL77KpPTigeXiZ7VPjBxFXoHIqyjyCvq83_dZd8k17mx92mulShttWx2WxQC93VfDFgl-j7px7XVo00WKKjVALzpt7j_HREh4U0DNh169h8H_P5dXd8_lNXqQd0uL0OwUHe821-4NgJedHqIjsRDDuE6H6GQ0HY9noTz7_nUC5Xgyu_wGtfN89Bf-Ou-w
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELZKkaAXxLsLBYwEJ7BwYie2DwghaLWl3YrDVtpbiF9oJTZZdret-qf4jczksStU0VtPOfgRa97OZOYj5I0rM6udiAyeksksSmacNizyzKsS_HkQWO88OsmHp_LbJJtskT99LQz-VtnbxMZQ-9rhN_IPYEZ1po3Mxaf5b4aoUZhd7SE0WrE4CpcXcGVbfjz8Cvx9m6YH--MvQ9ahCjAnVLZi4OK9SFXUAVyZcTaUkdvEpjLX1iSaS-9yFaXh3Dvt02CkEUFjnBFF6qQXsO8tcltiihH0R03Upslv0gCacQNGRBkjuyKdplQPQdM4Aw_JEGTFMP2vI7wS3V7JzDYO7-A-uddFqvRzK1oPyFaoHpI7oy4X_4jY7_tjuij9tF4tSgdRJIX4l14g3i6ztb-k04qeT89rOusReOl01mAi0TrSOVabYLdY2nTUDBVwAAsR6QwuBj9bzODlY3J6I7R9Qrarugq7hGJGNQ-JTYwpZWkj7Ba9V1x7BZdqrgck6clXuK6dOaJq_CrWjZgbkhdA8qIheQFr3q3XzNtmHtfO3uu5UnSKvSw2Yjggr9fDoJKYZymrUJ_hnLYy1ZgBedpyc_06obDBTgYj73v2bjb__1meXX-WV-TucDw6Lo4PT46ek520FTPGkz2yvVqchRcQOK3sy0ZaKflx0-rxF7mqJUE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VIlVcEOW50IKR4ARWndiJ7QNCVdtVS2nVQyvtLcQvtBKbLLvbVv1r_DrGeewKVfTWUw5-JJq3M575AD7YMjPK8kDxKajIgqDaKk0Dy5ws0Z97HuudT07zwwvxbZSN1uBPXwsTr1X2NrEx1K628R_5DppRlSktcr4TumsRZ_vDr9PfNCJIxUxrD6fRisixv7nG49v8y9E-8vpjmg4PzvcOaYcwQC2X2YKiu3c8lUF5dGvaGl8GZhKTilwZnSgmnM1lEJoxZ5VLvRaaexVjjsBTKxzHfR_AQ8mFiLARciRXDX-TBtyMaTQoUmvRFew0ZXsRQI1R9JY0Aq5oqv51irci3VtZ2sb5DZ_A4y5qJbutmG3Cmq-ewsZJl5d_Bubs4JzMSjeuF7PSYkRJMBYm1xF7l5ra3ZBxRa7GVzWZ9Gi8ZDxp8JFIHcg0Vp7EzrGk6a7pK-RGLEokEzwk_Gzxg-fP4eJeaPsC1qu68q-AxOxq7hOTaF2K0gTcLTgnmXISD9hMDSDpyVfYrrV5RNj4VSybMjckL5DkRUPyAtd8Wq6Zto097py91XOl6JR8XqxEcgDvl8OonjHnUla-voxz2ipVrQfwsuXm8nVcxmY7GY587tm72vz_3_L67m95BxuoGMX3o9PjN_AobaWMsmQL1hezS7-NMdTCvG2ElcCP-9aOv4N0KXQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=PET+radiotracers+for+whole-body+in+vivo+molecular+imaging+of+prostatic+neuroendocrine+malignancies&rft.jtitle=European+radiology&rft.au=Cohen%2C+Dan&rft.au=Hazut+Krauthammer%2C+Shir&rft.au=Fahoum%2C+Ibrahim&rft.au=Kesler%2C+Mikhail&rft.date=2023-09-01&rft.pub=Springer+Nature+B.V&rft.issn=0938-7994&rft.eissn=1432-1084&rft.volume=33&rft.issue=9&rft.spage=6502&rft.epage=6512&rft_id=info:doi/10.1007%2Fs00330-023-09619-8&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1432-1084&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1432-1084&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1432-1084&client=summon